HLA-B*5701 testing for all flucloxacillin starters is estimated to prevent 22 hypersensitivity reactions and 2 deaths per year, but almost 300,000 people would need to be genotyped for HLA-B*5701 each year. This evidence concerns the gene PPIB and hypersensitivity.